Stroke Risk and Tamoxifen Therapy for Breast Cancer

Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2004-10, Vol.96 (20), p.1528-1536
Hauptverfasser: Geiger, Ann M., Fischberg, Glenn M., Chen, Wansu, Bernstein, Leslie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1536
container_issue 20
container_start_page 1528
container_title JNCI : Journal of the National Cancer Institute
container_volume 96
creator Geiger, Ann M.
Fischberg, Glenn M.
Chen, Wansu
Bernstein, Leslie
description Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and known stroke risk factors. Methods: We conducted a nested case–control study of stroke after breast cancer among female Los Angeles County residents enrolled in a large health maintenance organization when diagnosed with breast cancer between January 1, 1980, and July 1, 2000. We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews. The association (odds ratio [OR] and 95% confidence interval [CI]) between tamoxifen and stroke risk was determined by using a conditional logistic regression model, adjusting for menopausal status and history of hypertension and diabetes. All statistical tests were two-sided. Results: Of 11 045 women with breast cancer, 179 met stroke eligibility criteria and were individually matched to two stroke-free control subjects with breast cancer on age and year of breast cancer diagnosis. The mean age at breast cancer diagnosis was 66.6 years (standard deviation [SD] = 12.3 years), and the mean at-risk period (i.e., the time between breast cancer diagnosis and first stroke or comparable time period for control subjects) was 5.7 years (SD = 4.5 years). Tamoxifen use was not associated with risk of stroke, either overall (OR = 1.0, 95% CI = 0.6 to 1.6) or in subgroups defined by duration, dose, or recency of use. Chemotherapy, but not a specific chemotherapy regimen, was associated with an increased risk of stroke, regardless of tamoxifen use (no tamoxifen use, OR = 2.8, 95% CI = 1.3 to 6.3; tamoxifen use OR = 2.2, 95% CI = 1.2 to 4.1). Conclusions: Tamoxifen use is not associated with increased stroke risk. Further exploration of possible increased stroke risk following chemotherapy treatment for breast cancer is needed.
doi_str_mv 10.1093/jnci/djh285
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17835698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>730747851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-9b0abb867fba7c8b1067f79e71e17e19292445d71a84cc1665966010ce53f23b3</originalsourceid><addsrcrecordid>eNpd0M9LwzAUwPEgipvTk3cpgl6kLi9Jk_SowzllIrgJ4iWkWcq6H-1MWtj-ezM2HJhLAvnweHwRugR8Dzil3Vlpiu5kNiUyOUJtYBzHBHByjNoYExFLKVgLnXk_w-GkhJ2iFiQsDY62ER3Vrprb6KPw80iXk2isl9W6yG0ZjafW6dUmyisXPTqrfR31dGmsO0cnuV54e7G_O-iz_zTuDeLh-_NL72EYG8ZkHacZ1lkmucgzLYzMAIenSK0AC8JCSsIuLJkI0JIZA5wnKecYsLEJzQnNaAfd7uauXPXTWF-rZeGNXSx0aavGKxCSJjyVAV7_g7OqcWXYTZGQggAIEtDdDhlXee9srlauWGq3UYDVNqTahlS7kEFf7Uc22dJODnZfLoCbPdDe6EXuQprCHxwnXHLOgot3rvC1Xf_9azdXXFCRqMHXt4LR6xj334ga0V-CbojG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221021172</pqid></control><display><type>article</type><title>Stroke Risk and Tamoxifen Therapy for Breast Cancer</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Geiger, Ann M. ; Fischberg, Glenn M. ; Chen, Wansu ; Bernstein, Leslie</creator><creatorcontrib>Geiger, Ann M. ; Fischberg, Glenn M. ; Chen, Wansu ; Bernstein, Leslie</creatorcontrib><description>Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and known stroke risk factors. Methods: We conducted a nested case–control study of stroke after breast cancer among female Los Angeles County residents enrolled in a large health maintenance organization when diagnosed with breast cancer between January 1, 1980, and July 1, 2000. We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews. The association (odds ratio [OR] and 95% confidence interval [CI]) between tamoxifen and stroke risk was determined by using a conditional logistic regression model, adjusting for menopausal status and history of hypertension and diabetes. All statistical tests were two-sided. Results: Of 11 045 women with breast cancer, 179 met stroke eligibility criteria and were individually matched to two stroke-free control subjects with breast cancer on age and year of breast cancer diagnosis. The mean age at breast cancer diagnosis was 66.6 years (standard deviation [SD] = 12.3 years), and the mean at-risk period (i.e., the time between breast cancer diagnosis and first stroke or comparable time period for control subjects) was 5.7 years (SD = 4.5 years). Tamoxifen use was not associated with risk of stroke, either overall (OR = 1.0, 95% CI = 0.6 to 1.6) or in subgroups defined by duration, dose, or recency of use. Chemotherapy, but not a specific chemotherapy regimen, was associated with an increased risk of stroke, regardless of tamoxifen use (no tamoxifen use, OR = 2.8, 95% CI = 1.3 to 6.3; tamoxifen use OR = 2.2, 95% CI = 1.2 to 4.1). Conclusions: Tamoxifen use is not associated with increased stroke risk. Further exploration of possible increased stroke risk following chemotherapy treatment for breast cancer is needed.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djh285</identifier><identifier>PMID: 15494603</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Adult ; Aged ; Antineoplastic Agents, Hormonal - administration &amp; dosage ; Antineoplastic Agents, Hormonal - adverse effects ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - prevention &amp; control ; Breast Neoplasms - radiotherapy ; Breast Neoplasms - surgery ; Case-Control Studies ; Chemotherapy ; Drug therapy ; Estrogen Antagonists - administration &amp; dosage ; Estrogen Antagonists - adverse effects ; Female ; Health risk assessment ; Humans ; Logistic Models ; Los Angeles ; Medical sciences ; Middle Aged ; Neurology ; Odds Ratio ; Patient Selection ; Risk Assessment ; Risk Factors ; Selective Estrogen Receptor Modulators - therapeutic use ; Stroke ; Stroke - chemically induced ; Tamoxifen - administration &amp; dosage ; Tamoxifen - adverse effects ; Tumors ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2004-10, Vol.96 (20), p.1528-1536</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 20, 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-9b0abb867fba7c8b1067f79e71e17e19292445d71a84cc1665966010ce53f23b3</citedby><cites>FETCH-LOGICAL-c448t-9b0abb867fba7c8b1067f79e71e17e19292445d71a84cc1665966010ce53f23b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16268664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15494603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geiger, Ann M.</creatorcontrib><creatorcontrib>Fischberg, Glenn M.</creatorcontrib><creatorcontrib>Chen, Wansu</creatorcontrib><creatorcontrib>Bernstein, Leslie</creatorcontrib><title>Stroke Risk and Tamoxifen Therapy for Breast Cancer</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>JNCI J Natl Cancer Inst</addtitle><description>Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and known stroke risk factors. Methods: We conducted a nested case–control study of stroke after breast cancer among female Los Angeles County residents enrolled in a large health maintenance organization when diagnosed with breast cancer between January 1, 1980, and July 1, 2000. We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews. The association (odds ratio [OR] and 95% confidence interval [CI]) between tamoxifen and stroke risk was determined by using a conditional logistic regression model, adjusting for menopausal status and history of hypertension and diabetes. All statistical tests were two-sided. Results: Of 11 045 women with breast cancer, 179 met stroke eligibility criteria and were individually matched to two stroke-free control subjects with breast cancer on age and year of breast cancer diagnosis. The mean age at breast cancer diagnosis was 66.6 years (standard deviation [SD] = 12.3 years), and the mean at-risk period (i.e., the time between breast cancer diagnosis and first stroke or comparable time period for control subjects) was 5.7 years (SD = 4.5 years). Tamoxifen use was not associated with risk of stroke, either overall (OR = 1.0, 95% CI = 0.6 to 1.6) or in subgroups defined by duration, dose, or recency of use. Chemotherapy, but not a specific chemotherapy regimen, was associated with an increased risk of stroke, regardless of tamoxifen use (no tamoxifen use, OR = 2.8, 95% CI = 1.3 to 6.3; tamoxifen use OR = 2.2, 95% CI = 1.2 to 4.1). Conclusions: Tamoxifen use is not associated with increased stroke risk. Further exploration of possible increased stroke risk following chemotherapy treatment for breast cancer is needed.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents, Hormonal - administration &amp; dosage</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - prevention &amp; control</subject><subject>Breast Neoplasms - radiotherapy</subject><subject>Breast Neoplasms - surgery</subject><subject>Case-Control Studies</subject><subject>Chemotherapy</subject><subject>Drug therapy</subject><subject>Estrogen Antagonists - administration &amp; dosage</subject><subject>Estrogen Antagonists - adverse effects</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Los Angeles</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Odds Ratio</subject><subject>Patient Selection</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Selective Estrogen Receptor Modulators - therapeutic use</subject><subject>Stroke</subject><subject>Stroke - chemically induced</subject><subject>Tamoxifen - administration &amp; dosage</subject><subject>Tamoxifen - adverse effects</subject><subject>Tumors</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0M9LwzAUwPEgipvTk3cpgl6kLi9Jk_SowzllIrgJ4iWkWcq6H-1MWtj-ezM2HJhLAvnweHwRugR8Dzil3Vlpiu5kNiUyOUJtYBzHBHByjNoYExFLKVgLnXk_w-GkhJ2iFiQsDY62ER3Vrprb6KPw80iXk2isl9W6yG0ZjafW6dUmyisXPTqrfR31dGmsO0cnuV54e7G_O-iz_zTuDeLh-_NL72EYG8ZkHacZ1lkmucgzLYzMAIenSK0AC8JCSsIuLJkI0JIZA5wnKecYsLEJzQnNaAfd7uauXPXTWF-rZeGNXSx0aavGKxCSJjyVAV7_g7OqcWXYTZGQggAIEtDdDhlXee9srlauWGq3UYDVNqTahlS7kEFf7Uc22dJODnZfLoCbPdDe6EXuQprCHxwnXHLOgot3rvC1Xf_9azdXXFCRqMHXt4LR6xj334ga0V-CbojG</recordid><startdate>20041020</startdate><enddate>20041020</enddate><creator>Geiger, Ann M.</creator><creator>Fischberg, Glenn M.</creator><creator>Chen, Wansu</creator><creator>Bernstein, Leslie</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope></search><sort><creationdate>20041020</creationdate><title>Stroke Risk and Tamoxifen Therapy for Breast Cancer</title><author>Geiger, Ann M. ; Fischberg, Glenn M. ; Chen, Wansu ; Bernstein, Leslie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-9b0abb867fba7c8b1067f79e71e17e19292445d71a84cc1665966010ce53f23b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents, Hormonal - administration &amp; dosage</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - prevention &amp; control</topic><topic>Breast Neoplasms - radiotherapy</topic><topic>Breast Neoplasms - surgery</topic><topic>Case-Control Studies</topic><topic>Chemotherapy</topic><topic>Drug therapy</topic><topic>Estrogen Antagonists - administration &amp; dosage</topic><topic>Estrogen Antagonists - adverse effects</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Los Angeles</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Odds Ratio</topic><topic>Patient Selection</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Selective Estrogen Receptor Modulators - therapeutic use</topic><topic>Stroke</topic><topic>Stroke - chemically induced</topic><topic>Tamoxifen - administration &amp; dosage</topic><topic>Tamoxifen - adverse effects</topic><topic>Tumors</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geiger, Ann M.</creatorcontrib><creatorcontrib>Fischberg, Glenn M.</creatorcontrib><creatorcontrib>Chen, Wansu</creatorcontrib><creatorcontrib>Bernstein, Leslie</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geiger, Ann M.</au><au>Fischberg, Glenn M.</au><au>Chen, Wansu</au><au>Bernstein, Leslie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stroke Risk and Tamoxifen Therapy for Breast Cancer</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>JNCI J Natl Cancer Inst</addtitle><date>2004-10-20</date><risdate>2004</risdate><volume>96</volume><issue>20</issue><spage>1528</spage><epage>1536</epage><pages>1528-1536</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and known stroke risk factors. Methods: We conducted a nested case–control study of stroke after breast cancer among female Los Angeles County residents enrolled in a large health maintenance organization when diagnosed with breast cancer between January 1, 1980, and July 1, 2000. We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews. The association (odds ratio [OR] and 95% confidence interval [CI]) between tamoxifen and stroke risk was determined by using a conditional logistic regression model, adjusting for menopausal status and history of hypertension and diabetes. All statistical tests were two-sided. Results: Of 11 045 women with breast cancer, 179 met stroke eligibility criteria and were individually matched to two stroke-free control subjects with breast cancer on age and year of breast cancer diagnosis. The mean age at breast cancer diagnosis was 66.6 years (standard deviation [SD] = 12.3 years), and the mean at-risk period (i.e., the time between breast cancer diagnosis and first stroke or comparable time period for control subjects) was 5.7 years (SD = 4.5 years). Tamoxifen use was not associated with risk of stroke, either overall (OR = 1.0, 95% CI = 0.6 to 1.6) or in subgroups defined by duration, dose, or recency of use. Chemotherapy, but not a specific chemotherapy regimen, was associated with an increased risk of stroke, regardless of tamoxifen use (no tamoxifen use, OR = 2.8, 95% CI = 1.3 to 6.3; tamoxifen use OR = 2.2, 95% CI = 1.2 to 4.1). Conclusions: Tamoxifen use is not associated with increased stroke risk. Further exploration of possible increased stroke risk following chemotherapy treatment for breast cancer is needed.</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>15494603</pmid><doi>10.1093/jnci/djh285</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8874
ispartof JNCI : Journal of the National Cancer Institute, 2004-10, Vol.96 (20), p.1528-1536
issn 0027-8874
1460-2105
language eng
recordid cdi_proquest_miscellaneous_17835698
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - adverse effects
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - prevention & control
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Case-Control Studies
Chemotherapy
Drug therapy
Estrogen Antagonists - administration & dosage
Estrogen Antagonists - adverse effects
Female
Health risk assessment
Humans
Logistic Models
Los Angeles
Medical sciences
Middle Aged
Neurology
Odds Ratio
Patient Selection
Risk Assessment
Risk Factors
Selective Estrogen Receptor Modulators - therapeutic use
Stroke
Stroke - chemically induced
Tamoxifen - administration & dosage
Tamoxifen - adverse effects
Tumors
Vascular diseases and vascular malformations of the nervous system
title Stroke Risk and Tamoxifen Therapy for Breast Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A05%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stroke%20Risk%20and%20Tamoxifen%20Therapy%20for%20Breast%20Cancer&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Geiger,%20Ann%20M.&rft.date=2004-10-20&rft.volume=96&rft.issue=20&rft.spage=1528&rft.epage=1536&rft.pages=1528-1536&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/10.1093/jnci/djh285&rft_dat=%3Cproquest_cross%3E730747851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221021172&rft_id=info:pmid/15494603&rfr_iscdi=true